Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioblastoma | 49 | 2024 | 3482 | 4.820 |
Why?
|
Brain Neoplasms | 80 | 2024 | 9025 | 4.600 |
Why?
|
Glioma | 23 | 2023 | 3452 | 1.670 |
Why?
|
Central Nervous System Neoplasms | 8 | 2023 | 915 | 1.530 |
Why?
|
Neovascularization, Pathologic | 9 | 2024 | 2636 | 1.120 |
Why?
|
Quinazolines | 10 | 2017 | 1371 | 1.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 7 | 2018 | 2787 | 1.020 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2024 | 9278 | 0.800 |
Why?
|
Angiogenesis Inhibitors | 12 | 2021 | 2047 | 0.770 |
Why?
|
Capillary Permeability | 2 | 2019 | 773 | 0.760 |
Why?
|
Meningeal Neoplasms | 7 | 2022 | 1246 | 0.760 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 11733 | 0.750 |
Why?
|
Magnetic Resonance Imaging | 42 | 2024 | 36415 | 0.730 |
Why?
|
Antineoplastic Agents | 12 | 2023 | 13632 | 0.630 |
Why?
|
Immunotherapy, Adoptive | 4 | 2024 | 1468 | 0.630 |
Why?
|
Ependymoma | 2 | 2021 | 320 | 0.630 |
Why?
|
Vascular Endothelial Growth Factor A | 8 | 2020 | 3493 | 0.620 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2017 | 664 | 0.620 |
Why?
|
Diffusion Tensor Imaging | 3 | 2023 | 2401 | 0.590 |
Why?
|
Dacarbazine | 6 | 2021 | 559 | 0.580 |
Why?
|
Isocitrate Dehydrogenase | 8 | 2022 | 937 | 0.550 |
Why?
|
Glutarates | 5 | 2018 | 243 | 0.550 |
Why?
|
Snake Venoms | 1 | 2015 | 38 | 0.500 |
Why?
|
Brain Stem Neoplasms | 1 | 2017 | 189 | 0.480 |
Why?
|
Diagnostic Imaging | 6 | 2022 | 3534 | 0.480 |
Why?
|
Meningioma | 3 | 2022 | 1216 | 0.470 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2018 | 617 | 0.460 |
Why?
|
Anticonvulsants | 3 | 2024 | 1910 | 0.460 |
Why?
|
Quinolines | 2 | 2016 | 764 | 0.450 |
Why?
|
Positron-Emission Tomography | 9 | 2023 | 6586 | 0.440 |
Why?
|
Image Processing, Computer-Assisted | 12 | 2023 | 8998 | 0.440 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.430 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2012 | 1372 | 0.430 |
Why?
|
Tumor Microenvironment | 5 | 2024 | 3875 | 0.430 |
Why?
|
Cancer Vaccines | 2 | 2017 | 1038 | 0.410 |
Why?
|
Patient Care | 1 | 2018 | 623 | 0.410 |
Why?
|
Magnetic Resonance Spectroscopy | 8 | 2022 | 3770 | 0.400 |
Why?
|
Disease-Free Survival | 14 | 2021 | 6819 | 0.390 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2012 | 646 | 0.360 |
Why?
|
Humans | 122 | 2024 | 761222 | 0.360 |
Why?
|
Meningeal Carcinomatosis | 2 | 2021 | 63 | 0.350 |
Why?
|
T-Lymphocytes | 3 | 2024 | 10203 | 0.350 |
Why?
|
Pyridines | 5 | 2022 | 2872 | 0.350 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5301 | 0.340 |
Why?
|
Methotrexate | 4 | 2012 | 1718 | 0.340 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 83 | 0.330 |
Why?
|
Lymphoma | 3 | 2023 | 1898 | 0.310 |
Why?
|
Phthalazines | 1 | 2010 | 383 | 0.290 |
Why?
|
Oxazines | 2 | 2020 | 349 | 0.290 |
Why?
|
Radiotherapy | 3 | 2010 | 1500 | 0.280 |
Why?
|
Apraxias | 1 | 2007 | 58 | 0.270 |
Why?
|
Prognosis | 15 | 2024 | 29688 | 0.270 |
Why?
|
Blood-Brain Barrier | 2 | 2016 | 1028 | 0.260 |
Why?
|
Aged | 42 | 2024 | 169292 | 0.260 |
Why?
|
Infarction, Anterior Cerebral Artery | 1 | 2005 | 12 | 0.260 |
Why?
|
Aphasia | 1 | 2007 | 192 | 0.240 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1784 | 0.240 |
Why?
|
Adult | 45 | 2024 | 221120 | 0.240 |
Why?
|
Brain Edema | 1 | 2009 | 604 | 0.240 |
Why?
|
Middle Aged | 45 | 2024 | 220858 | 0.230 |
Why?
|
Combined Modality Therapy | 6 | 2024 | 8519 | 0.230 |
Why?
|
Tremor | 1 | 2005 | 190 | 0.230 |
Why?
|
Brain | 20 | 2023 | 27094 | 0.220 |
Why?
|
Male | 52 | 2024 | 360703 | 0.210 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2024 | 326 | 0.210 |
Why?
|
Syncope | 1 | 2005 | 428 | 0.200 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 883 | 0.190 |
Why?
|
Female | 54 | 2024 | 392552 | 0.190 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5665 | 0.190 |
Why?
|
Survival Rate | 9 | 2018 | 12728 | 0.180 |
Why?
|
Contrast Media | 6 | 2020 | 5311 | 0.180 |
Why?
|
Inositol | 1 | 2021 | 215 | 0.180 |
Why?
|
Craniopharyngioma | 1 | 2023 | 276 | 0.180 |
Why?
|
Hodgkin Disease | 1 | 2008 | 1379 | 0.180 |
Why?
|
Cranial Irradiation | 2 | 2015 | 390 | 0.170 |
Why?
|
Misonidazole | 2 | 2018 | 33 | 0.170 |
Why?
|
Ischemic Attack, Transient | 1 | 2005 | 874 | 0.170 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 301 | 0.170 |
Why?
|
Gliosarcoma | 1 | 2020 | 114 | 0.170 |
Why?
|
Treatment Outcome | 17 | 2024 | 64681 | 0.160 |
Why?
|
Immunotherapy | 3 | 2024 | 4642 | 0.160 |
Why?
|
Anilides | 2 | 2019 | 411 | 0.160 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 94 | 0.160 |
Why?
|
Valproic Acid | 1 | 2021 | 443 | 0.160 |
Why?
|
Glycine | 1 | 2022 | 659 | 0.160 |
Why?
|
Spinal Cord Neoplasms | 1 | 2021 | 261 | 0.160 |
Why?
|
Follow-Up Studies | 10 | 2024 | 39127 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 348 | 0.150 |
Why?
|
Carotid Stenosis | 1 | 2005 | 859 | 0.150 |
Why?
|
Pyrimidines | 2 | 2020 | 3027 | 0.150 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2016 | 1655 | 0.140 |
Why?
|
Carboplatin | 1 | 2020 | 793 | 0.140 |
Why?
|
Angiopoietins | 1 | 2017 | 86 | 0.140 |
Why?
|
Brain Diseases | 2 | 2024 | 1545 | 0.140 |
Why?
|
Laboratories | 1 | 2021 | 462 | 0.140 |
Why?
|
Vaccines, Subunit | 1 | 2017 | 157 | 0.140 |
Why?
|
Spinal Nerve Roots | 1 | 2017 | 121 | 0.140 |
Why?
|
Immunity | 1 | 2023 | 996 | 0.140 |
Why?
|
Disease Progression | 7 | 2023 | 13511 | 0.140 |
Why?
|
Dexamethasone | 1 | 2024 | 1945 | 0.140 |
Why?
|
Postoperative Period | 1 | 2021 | 1818 | 0.140 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 4909 | 0.140 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 183 | 0.130 |
Why?
|
Blood Vessels | 2 | 2014 | 1111 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10756 | 0.130 |
Why?
|
Lithium | 1 | 2019 | 596 | 0.130 |
Why?
|
Diagnostic Tests, Routine | 1 | 2021 | 788 | 0.130 |
Why?
|
Blood Volume Determination | 1 | 2015 | 41 | 0.130 |
Why?
|
Clinical Trials as Topic | 8 | 2024 | 8002 | 0.130 |
Why?
|
DNA Methylation | 1 | 2009 | 4384 | 0.120 |
Why?
|
Postoperative Care | 2 | 2019 | 1468 | 0.120 |
Why?
|
Seizures | 3 | 2024 | 2965 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2549 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2023 | 2054 | 0.120 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1322 | 0.120 |
Why?
|
Mutation | 12 | 2024 | 30004 | 0.120 |
Why?
|
Melanoma | 2 | 2023 | 5694 | 0.110 |
Why?
|
Neurosurgical Procedures | 3 | 2024 | 2067 | 0.110 |
Why?
|
Algorithms | 8 | 2024 | 14025 | 0.110 |
Why?
|
Receptors, CXCR4 | 1 | 2018 | 727 | 0.110 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 1008 | 0.110 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4851 | 0.110 |
Why?
|
Survival Analysis | 4 | 2021 | 10088 | 0.110 |
Why?
|
Radiometry | 1 | 2018 | 812 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3512 | 0.100 |
Why?
|
Young Adult | 13 | 2021 | 59222 | 0.100 |
Why?
|
Astrocytoma | 1 | 2017 | 774 | 0.100 |
Why?
|
Neurofibromatosis 2 | 1 | 2016 | 383 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 890 | 0.100 |
Why?
|
Dementia | 1 | 2007 | 2684 | 0.100 |
Why?
|
Neuroma, Acoustic | 1 | 2016 | 458 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2018 | 563 | 0.100 |
Why?
|
src-Family Kinases | 1 | 2014 | 536 | 0.100 |
Why?
|
Administration, Oral | 2 | 2017 | 4015 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 546 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 4 | 2018 | 4052 | 0.090 |
Why?
|
Bayes Theorem | 2 | 2016 | 2329 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2019 | 1405 | 0.090 |
Why?
|
Aged, 80 and over | 13 | 2021 | 58952 | 0.090 |
Why?
|
Enzyme Inhibitors | 2 | 2020 | 3702 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2058 | 0.090 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2016 | 3366 | 0.090 |
Why?
|
Piperazines | 2 | 2021 | 2522 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6486 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2020 | 2864 | 0.090 |
Why?
|
Image Enhancement | 2 | 2018 | 2888 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 176 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2018 | 2684 | 0.090 |
Why?
|
Epilepsy | 2 | 2024 | 3304 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 694 | 0.080 |
Why?
|
Nitriles | 1 | 2014 | 971 | 0.080 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2011 | 170 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 636 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1073 | 0.080 |
Why?
|
Models, Biological | 3 | 2016 | 9458 | 0.080 |
Why?
|
Hearing Loss | 1 | 2016 | 782 | 0.080 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20982 | 0.080 |
Why?
|
Head | 1 | 2014 | 922 | 0.070 |
Why?
|
Prospective Studies | 5 | 2021 | 54437 | 0.070 |
Why?
|
Autopsy | 2 | 2013 | 1010 | 0.070 |
Why?
|
Nausea | 2 | 2021 | 678 | 0.070 |
Why?
|
Paraneoplastic Syndromes | 2 | 1999 | 155 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4574 | 0.070 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1405 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 558 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 15308 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 4 | 2020 | 3726 | 0.070 |
Why?
|
Consensus | 3 | 2020 | 3134 | 0.070 |
Why?
|
Injections, Spinal | 1 | 2007 | 317 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2018 | 11119 | 0.070 |
Why?
|
Camptothecin | 1 | 2009 | 591 | 0.070 |
Why?
|
Time | 1 | 2008 | 545 | 0.060 |
Why?
|
Tumor Burden | 2 | 2023 | 1892 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13386 | 0.060 |
Why?
|
Alzheimer Disease | 1 | 2007 | 8606 | 0.060 |
Why?
|
Circle of Willis | 1 | 2005 | 78 | 0.060 |
Why?
|
Anterior Cerebral Artery | 1 | 2005 | 50 | 0.060 |
Why?
|
Permeability | 1 | 2007 | 721 | 0.060 |
Why?
|
Neoplasms | 4 | 2021 | 22142 | 0.060 |
Why?
|
Tissue Distribution | 2 | 2020 | 2263 | 0.060 |
Why?
|
Paresis | 1 | 2005 | 176 | 0.060 |
Why?
|
Ultrasonography, Doppler, Transcranial | 1 | 2005 | 281 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12474 | 0.050 |
Why?
|
Benchmarking | 2 | 2024 | 1045 | 0.050 |
Why?
|
Antigens | 2 | 1999 | 1441 | 0.050 |
Why?
|
Child | 4 | 2024 | 80154 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4872 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4373 | 0.050 |
Why?
|
Databases, Factual | 1 | 2018 | 7965 | 0.050 |
Why?
|
Perfusion | 2 | 2019 | 1390 | 0.050 |
Why?
|
Mice, Nude | 2 | 2020 | 3606 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2023 | 80675 | 0.050 |
Why?
|
Recurrence | 2 | 2020 | 8457 | 0.050 |
Why?
|
Arm | 1 | 2005 | 589 | 0.050 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 185 | 0.050 |
Why?
|
Oxygen | 1 | 2013 | 4228 | 0.050 |
Why?
|
Genomics | 3 | 2024 | 5829 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 152 | 0.050 |
Why?
|
Autoantibodies | 2 | 2000 | 2119 | 0.050 |
Why?
|
Antibodies | 1 | 2009 | 2415 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2010 | 1878 | 0.050 |
Why?
|
Medical Oncology | 1 | 2012 | 2320 | 0.040 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2000 | 24 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2017 | 12976 | 0.040 |
Why?
|
Leg | 1 | 2005 | 1087 | 0.040 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2020 | 102 | 0.040 |
Why?
|
Endarterectomy, Carotid | 1 | 2005 | 554 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
Adolescent | 5 | 2021 | 88300 | 0.040 |
Why?
|
Arginine | 1 | 2022 | 920 | 0.040 |
Why?
|
Causality | 1 | 2005 | 1244 | 0.040 |
Why?
|
Antibodies, Neoplasm | 1 | 2000 | 282 | 0.040 |
Why?
|
Genes, myc | 1 | 2020 | 390 | 0.040 |
Why?
|
DNA Helicases | 1 | 2024 | 850 | 0.040 |
Why?
|
Functional Laterality | 1 | 2005 | 2257 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14610 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2007 | 1600 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1895 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2005 | 1432 | 0.040 |
Why?
|
Immune Sera | 1 | 1999 | 605 | 0.040 |
Why?
|
Macrophages | 1 | 2013 | 5755 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2018 | 166 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2014 | 2854 | 0.040 |
Why?
|
Cohort Studies | 5 | 2019 | 41496 | 0.040 |
Why?
|
Motor Cortex | 1 | 2005 | 1006 | 0.040 |
Why?
|
Lomustine | 1 | 2017 | 60 | 0.040 |
Why?
|
Remission Induction | 1 | 2023 | 2392 | 0.040 |
Why?
|
Pattern Recognition, Automated | 1 | 2023 | 993 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 559 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 247 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 245 | 0.040 |
Why?
|
Automation | 1 | 2019 | 585 | 0.030 |
Why?
|
Ganglia, Spinal | 1 | 2000 | 525 | 0.030 |
Why?
|
Hypesthesia | 1 | 2017 | 106 | 0.030 |
Why?
|
Vomiting | 1 | 2020 | 650 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15920 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2018 | 270 | 0.030 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
Odds Ratio | 1 | 2009 | 9652 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1333 | 0.030 |
Why?
|
4-1BB Ligand | 1 | 2016 | 29 | 0.030 |
Why?
|
Peripheral Nervous System | 1 | 2017 | 151 | 0.030 |
Why?
|
Neurons | 3 | 2019 | 9429 | 0.030 |
Why?
|
OX40 Ligand | 1 | 2016 | 57 | 0.030 |
Why?
|
Phantoms, Imaging | 2 | 2016 | 2513 | 0.030 |
Why?
|
Brain Mapping | 1 | 2011 | 6635 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1666 | 0.030 |
Why?
|
Antineoplastic Protocols | 1 | 2015 | 48 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2643 | 0.030 |
Why?
|
Encephalitis | 1 | 1999 | 438 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 551 | 0.030 |
Why?
|
Incidence | 1 | 2013 | 21366 | 0.030 |
Why?
|
Animals | 8 | 2020 | 168089 | 0.030 |
Why?
|
Gadolinium | 1 | 2020 | 961 | 0.030 |
Why?
|
Physical Phenomena | 1 | 2014 | 48 | 0.030 |
Why?
|
Immunohistochemistry | 4 | 2015 | 11067 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1550 | 0.030 |
Why?
|
Signal Transduction | 3 | 2018 | 23419 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 566 | 0.030 |
Why?
|
Cerebrospinal Fluid | 1 | 2017 | 544 | 0.030 |
Why?
|
K562 Cells | 1 | 2016 | 640 | 0.030 |
Why?
|
Muscle Weakness | 1 | 2017 | 412 | 0.030 |
Why?
|
Skull | 1 | 2018 | 818 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2007 | 7046 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1618 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2010 | 7851 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2000 | 1988 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1052 | 0.030 |
Why?
|
Disease Management | 1 | 2024 | 2507 | 0.030 |
Why?
|
Infusions, Intraventricular | 1 | 2012 | 32 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1234 | 0.030 |
Why?
|
Testicular Neoplasms | 1 | 1999 | 801 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2013 | 210 | 0.030 |
Why?
|
Age Factors | 1 | 2009 | 18384 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9187 | 0.030 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2014 | 254 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3446 | 0.030 |
Why?
|
Transcription Factors | 2 | 2024 | 12101 | 0.030 |
Why?
|
Neuroprotective Agents | 1 | 2019 | 956 | 0.020 |
Why?
|
Neuroblastoma | 1 | 2000 | 1246 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2010 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2018 | 961 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3821 | 0.020 |
Why?
|
Microcirculation | 1 | 2016 | 1280 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2013 | 346 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1964 | 0.020 |
Why?
|
Sarcoidosis | 1 | 2017 | 537 | 0.020 |
Why?
|
Reference Standards | 1 | 2015 | 1005 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1375 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 943 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 2024 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2016 | 2112 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 16954 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1256 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4243 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1624 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3584 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2016 | 801 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1703 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2015 | 1436 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2016 | 1490 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2024 | 5783 | 0.020 |
Why?
|
United States | 1 | 2017 | 72341 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2011 | 696 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2553 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2813 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1409 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2017 | 1876 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4303 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 1540 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 1999 | 4404 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3803 | 0.020 |
Why?
|
Hemodynamics | 1 | 2016 | 4165 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1625 | 0.020 |
Why?
|
Piperidines | 1 | 2014 | 1656 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15545 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12341 | 0.020 |
Why?
|
Gene Expression | 1 | 2018 | 7571 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5478 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12052 | 0.010 |
Why?
|
Tuberculosis | 1 | 2017 | 2017 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6067 | 0.010 |
Why?
|
Vaccination | 1 | 2016 | 3369 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 2803 | 0.010 |
Why?
|
Rats | 4 | 2000 | 23705 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6224 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5871 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4009 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20588 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8531 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 22174 | 0.010 |
Why?
|
Models, Statistical | 1 | 2016 | 5081 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2018 | 26200 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26072 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2012 | 2223 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 17348 | 0.010 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2000 | 8 | 0.010 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2000 | 9 | 0.010 |
Why?
|
Infant | 2 | 2018 | 36170 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6781 | 0.010 |
Why?
|
Child, Preschool | 2 | 2018 | 42225 | 0.010 |
Why?
|
Electric Conductivity | 1 | 2000 | 405 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10218 | 0.010 |
Why?
|
Receptors, Purinergic P2 | 1 | 2000 | 150 | 0.010 |
Why?
|
Purkinje Cells | 1 | 2000 | 226 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20118 | 0.010 |
Why?
|
Limbic System | 1 | 1999 | 419 | 0.010 |
Why?
|
Apoptosis | 1 | 2012 | 9478 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1999 | 1989 | 0.010 |
Why?
|
Brain Chemistry | 1 | 1999 | 959 | 0.010 |
Why?
|
Testis | 1 | 1999 | 781 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2000 | 1527 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2012 | 11512 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 24022 | 0.010 |
Why?
|
Glutamic Acid | 1 | 2000 | 1173 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1999 | 12747 | 0.010 |
Why?
|
Brain Stem | 1 | 1999 | 858 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2000 | 1668 | 0.010 |
Why?
|
Drug Resistance | 1 | 2000 | 1594 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1999 | 4167 | 0.010 |
Why?
|
Cerebellum | 1 | 2000 | 1501 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81330 | 0.010 |
Why?
|
Blotting, Western | 1 | 2000 | 5032 | 0.010 |
Why?
|
Epitopes | 1 | 1999 | 2504 | 0.010 |
Why?
|
Kinetics | 1 | 2000 | 6312 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1999 | 1985 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2000 | 4537 | 0.000 |
Why?
|
Base Sequence | 1 | 1999 | 12404 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 13402 | 0.000 |
Why?
|
Hippocampus | 1 | 1999 | 3754 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1999 | 17598 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2000 | 18927 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 2000 | 5775 | 0.000 |
Why?
|
Time Factors | 1 | 2000 | 39957 | 0.000 |
Why?
|